Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CO-STAR: De-escalation Strategies in Early Rheumatoid Arthritis
NCT02466581Phase 4Unknown
- Sponsor
- Karolinska Institutet
- Start
- Feb 2015
- Primary completion
- Jul 2023
- Modality
- Antibody Fragments, Polymer-based Nanoparticles, Antibody Conjugates
- Countries
- 1
01
Overview
A Phase 4 trial of certolizumab pegol, abatacept, tocilizumab, 5-aminosalicylic acid + sulphasalazine, hydroxychloroquine in rheumatoid arthritis (RA), sponsored by Karolinska Institutet. Status: unknown.
02
Drugs
certolizumab pegolabatacepttocilizumab5-aminosalicylic acid + sulphasalazinehydroxychloroquine
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02466581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02466581.